I'm of the view that if bioasis had the cure for cancer, they might be able to demonstrate it in mice but the management team is too inept to 1) get it to the clinic and 2) deliver any shareholder benefit.  I continue to be negative exactly because I hold a relevant long position.  I want leadership replaced.  Anyone who can actively manage a plan of xb3 to the clinic sometime in 2022 is miles better than what currently exists.

So, from my perspective anyone who continues supporting the status quo is actively undermining the long term value of bioasis.